The Anti-Hiv Drug Nelfinavir Mesylate (Viracept) Is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting Further Evaluation as an Antiviral Against COVID-19 Infections

doi 10.1101/2020.04.24.060376
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cold Spring Harbor Laboratory

Related search

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2020English

Hypothesis: Advanced Biotechnological Treatment Approaches Against SARS-CoV-2 (COVID-19)

Volume 5 - 2020, Issue 4 - April
2020English

Detection of Antibodies Against SARS-CoV-2 in Patients With COVID-19

Journal of Medical Virology
VirologyInfectious Diseases
2020English

Lessons Unfolding From Pediatric Cases of COVID-19 Disease Caused by SARS-CoV-2 Infection

Pediatric Pulmonology
Child HealthPulmonaryPediatricsPerinatologyRespiratory Medicine
2020English

A SARS-CoV-2/COVID-19 Em Pacientes Com Câncer

Revista Brasileira de Cancerologia
2020English

Update on the SARS-CoV-2 (COVID-19) Outbreak: A Global Pandemic Challenge

2020English

Important Steps to Control COVID-19/SARS-CoV-2 Infection

SN Comprehensive Clinical Medicine
2020English

Call for Papers: The Pathophysiology of COVID-19 and SARS-CoV-2 Infection

American Journal of Physiology - Lung Cellular and Molecular Physiology
PulmonaryRespiratory MedicinePhysiologyCell Biology
2020English

Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study

2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy